$1.56
0.65% yesterday
Nasdaq, Oct 15, 10:04 pm CET
ISIN
US09060U5074
Symbol
BCDA

BioCardia Inc. Stock price

$1.56
-0.59 27.44% 1M
-0.49 23.90% 6M
-0.62 28.44% YTD
-0.88 36.07% 1Y
-29.04 94.90% 3Y
-33.99 95.61% 5Y
-119.94 98.72% 10Y
-2,347.44 99.93% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
+0.01 0.65%
ISIN
US09060U5074
Symbol
BCDA
Industry

Key metrics

Basic
Market capitalization
$16.6m
Enterprise Value
$15.6m
Net debt
positive
Cash
$980.0k
Shares outstanding
5.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 324.5
EV/Sales
- | 305.3
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
22.5%
Return on Equity
-949.3%
ROCE
571.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $51.0k
EBITDA
$-8.8m | $-11.2m
EBIT
$-8.9m | $-9.4m
Net Income
$-8.8m | $-5.9m
Free Cash Flow
$-8.5m
Growth (TTM | estimate)
Revenue
-100.0% | -15.0%
EBITDA
-3.3% | -41.5%
EBIT
-2.9% | -17.0%
Net Income
-2.7% | 25.9%
Free Cash Flow
-19.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -22,000.0%
EBIT
-
Net
- | -11,550.0%
Free Cash Flow
-
More
EPS
$-1.7
FCF per Share
$-1.5
Short interest
2.0%
Employees
19
Rev per Employee
$0.0
Show more

Is BioCardia Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

BioCardia Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a BioCardia Inc. forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a BioCardia Inc. forecast:

Buy
88%
Hold
13%

Financial data from BioCardia Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 3.61 3.61
9% 9%
-
- Research and Development Expense 5.24 5.24
3% 3%
-
-8.81 -8.81
3% 3%
-
- Depreciation and Amortization 0.05 0.05
38% 38%
-
EBIT (Operating Income) EBIT -8.85 -8.85
3% 3%
-
Net Profit -8.79 -8.79
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about BioCardia Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

BioCardia Inc. Stock News

Neutral
GlobeNewsWire
14 days ago
SUNNYVALE, Calif., Oct. 02, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has regained compliance with the Nasdaq Capital Market's Listing Requirements (the “Listing Requirements”). This confirmation follows the Company's successful efforts to improve its bal...
Neutral
GlobeNewsWire
28 days ago
$6 million upfront with up to an additional $6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants $6 million upfront with up to an additional $6 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
Neutral
GlobeNewsWire
28 days ago
SUNNYVALE, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioCardia, Inc. (NASDAQ: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial.
More BioCardia Inc. News

Company Profile

BioCardia, Inc. operates as a clinical-stage regenerative medicine company. It develops novel therapeutics for cardiovascular diseases. The firm offers proprietary comprehensive biotherapeutic solutions for cardiovascular disease under the CardiAMP and CardiALLO brand. It operates in only one business segment, which is a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. The company was founded on January 12, 1994 and is headquartered in San Carlos, CA.

Head office United States
CEO Peter Altman
Employees 19
Founded 1994
Website www.biocardia.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today